Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltartoxatug vs Human Tetanus Immunoglobulin for Prevention of Tetanus in High-Risk Severe Trauma Patients
ChiCTR2600125554Phase 4Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of siltartoxatug in Tetanus (2 arms), sponsored by Changzhou First People's Hospital. Primary endpoint: Proportion of subjects with anti-tetanus neutralizing antibody titer ΔTiter ≥ 0.01 IU/mL at 8 hours after administration. Planned start May 2026; status: not yet recruiting.
02
Drugs
siltartoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on ChiCTR2600125554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125554.